0000950170-24-028188.txt : 20240307
0000950170-24-028188.hdr.sgml : 20240307
20240307174521
ACCESSION NUMBER: 0000950170-24-028188
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240307
DATE AS OF CHANGE: 20240307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Glover Stephen C.
CENTRAL INDEX KEY: 0001304406
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-56600
FILM NUMBER: 24731553
MAIL ADDRESS:
STREET 1: 108 DOCKSIDE CIRCLE
CITY: WESTON
STATE: FL
ZIP: 33327
FORMER NAME:
FORMER CONFORMED NAME: Glover Steve C
DATE OF NAME CHANGE: 20040927
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ambrx Biopharma, Inc.
CENTRAL INDEX KEY: 0001990550
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 932892120
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10975 NORTH TORREY PINES ROAD
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: (858) 875-2400
MAIL ADDRESS:
STREET 1: 10975 NORTH TORREY PINES ROAD
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: New Ambrx Biopharma Inc.
DATE OF NAME CHANGE: 20230818
4
1
ownership.xml
4
X0508
4
2024-03-07
true
0001990550
Ambrx Biopharma, Inc.
AMAM
0001304406
Glover Stephen C.
C/O AMBRX BIOPHARMA INC.,
10975 N TORREY PINES ROAD
LA JOLLA
CA
92037
true
false
false
false
false
Restricted Stock Units
2024-03-07
4
D
false
12142
D
Common Stock
12142
0
D
Option to Purchase Common Stock
13.79
2024-03-07
4
D
false
30000
D
2033-05-18
Common Stock
30000
0
D
Option to Purchase Common Stock
13.79
2024-03-07
4
D
false
2500
D
2033-05-18
Common Stock
2500
0
D
Option to Purchase Common Stock
13.72
2024-03-07
4
D
false
5714
D
2033-06-07
Common Stock
5714
0
D
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J.
Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock").
These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting.
Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU.
The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest in thirty-six (36) equal monthly installments following May 19, 2023.
Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.
These Company Options are fully vested and exercisable.
The Company Common Stock subject to the Company Options vest on June 7, 2024.
/s/ Sonja Nelson, Attorney-in-Fact for Steven C. Glover
2024-03-07